ITM Isotope Technologies Munich SE, Germany, an established  radiopharmaceutical biotech company, and the Australian Nuclear Science and Technology Organization (ANSTO), a public research organization and international player in the field of nuclear science and technology, have announced the extension of their partnership by entering into a further long-term licensing agreement. Under the terms of the agreement, ANSTO will continue producing n.c.a. ¹⁷⁷Lu for the Australian and New Zealand markets by utilizing ITM’s unique production technology, continuing to address the needs of patients, clinicians and partners alike. ITM retains all intellectual property rights to the medical radioisotope. Further details of the agreement were not disclosed.

N.c.a. ¹⁷⁷Lu is used as a radiopharmaceutical precursor in Targeted Radionuclide Therapy, a novel treatment regimen in precision oncology. Due to the rise of Targeted Radionuclide Therapy, the global demand for medical radioisotopes is growing significantly. The agreement between ITM and ANSTO directly addresses this demand and further solidifies ITM’s established global network, which ensures clinics and patients around the world have reliable, timely access to high value medical radioisotopes.

To read more please visit:

ITM and ANSTO Announce Extension of Licensing Agreement for the Production and Supply of the Medical Radioisotope n.c.a. Lutetium-177

Source: ITM